A Pilot, Proof of Concept, Placebo-controlled, Parallel Study of the Effects of High Dose Intranasal Oxytocin for the Treatment of Tinnitus
Phase: PHASE3
Conditions: Tinnitus
Sponsor: NYU Langone Health

 
 
 
 
 
A pilot, proof of concept, placebo-controlled, parallel study of the 
effects of high dose intranasal oxytocin for the treatment of tinnitus 
 
 
Principal Investigator: 
 
Lawrence Newman, MD 
Department of Neurology  
NYU Langone Preston Robert Tisch Center for Men's Health 
555 Madison Avenue, 3rd Floor 
Lawrence.Newman@nyulangone.org 
(646)754 - 2000 
NYULMC Study Number: 
s19 - 01381  
Study Product: 
Intranasal Oxytocin 
ClinicalTrials.gov 
Number                 
NCT04210310 
 
Initial version: 14 January 2020 
Amended: 
6 March 2020 
Amended: 
7 July 2020 
Amended: 
31 December 2020 
Amended:          6 April 2021  
Amended:          17 May 2021 
Amended:          6 July 2021 
Amended:          16 November 2021 
 
 
Tool Revision History: 
 
Version Number 
Version Date 
Summary of Revisions Made 
1.0 
14 JAN 2020 
Original version 
1.1 
6 MAR 2020 
Modified Visit 2 (Baseline Visit) to be a phone visit instead of 
an office study visit. 
1.2 
7 JUL 2020 
Changed compounding pharmacy to New Drug Loft/VLS 
Pharmacy due to issues with Town TOTAL Compounding 
Pharmacy’s quality control. Accordingly, the placebo formula 
has been modified to include the same inactive ingredients 
as the oxytocin nasal spray to mirror the consistency of the 
active drug. The new Headache Fellow has been added to 
the IRB application.  
1.3 
31 DEC 2020 
Modified the time period subjects receive the minimum dose 
of 30 IU oxytocin from 3 weeks to 2 weeks to allow subjects 
to reach the maximum dose of 45 IU before randomization 
occurs, since study drug is dispensed every 2 weeks. Also, 
per the Conflict of Interest Management Unit, the physician 
overseeing the Data Safety Monitoring of the study has been 

changed from Dr. Thomas Berk to Dr. Scott Grossman, a 
disinterested third party. 
1.4 
6 APR 2021 
Modified to include the potential risk of acute pulmonary 
edema after one participant experienced this unanticipated 
event while using the compounded oxytocin nasal spray. 
Exclusion criteria revised to include history of pulmonary 
edema, CHF, and severe renal disease. 
1.5 
17 MAY 2021 
Modified to increase the number of participants screened to 
50, with the same goal of enrolling 30 participants in the 
study. This number has been modified to account for the 
larger number of participants who failed screening due to 
abnormal results, as well as the participants who were 
enrolled and withdrew due to noncompliance, adverse 
events, or hesitance to travel during the pandemic. 
1.6 
6 JUL 2021 
Modified to replace the previous Headache Fellow and Sub-
Investigator, Dr. Huang, with the new fellow, Dr. Thaler. Dr. 
Huang completed his fellowship and is no longer at this site. 
Dr. Thaler has been trained on the randomization 
procedures for this study. 
1.7 
16 NOV 2021 
Modified to add Dr. Tamimi, another new Headache Fellow, 
to the study team. He has also been trained on the 
randomization procedures for the study.  
 
Also, Section 5.7.2, Handling of Participant Withdrawals or 
Termination, has been modified to state that we plan to 
replace participants who withdraw or discontinue the study 
early. This is being changed to allow for the necessary data 
collection outlined in Section 9.3, Analysis Datasets, of the 
Statistical Considerations; data will be analyzed from 
participants who receive at least one dose of the study drug 
during the non-blinded phase, and also pass the 2-week 
washout period in the double-blind phase. In order to capture 
this data to determine efficacy of the drug, 30 participants 
must complete all visits through Week 12 of the study (Visit 
14). This can only be done if we replace the participants who 
withdraw or discontinue the study early. The number of 
participants screened will remain unchanged since Version 
1.5 of the protocol, at 50.  
Statement of Compliance 
This study will be conducted in accordance with the Code of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), 21 CFR Parts 50, 56, 312, and 812 as applicable, any other applicable 
US government research regulations, and institutional research policies and procedures. The International 
Conference on Harmonisation (“ICH”) Guideline for Good Clinical Practice (“GCP”) (sometimes referred to 
as “ICH-GCP” or “E6”) will be applied only to the extent that it is compatible with FDA and DHHS regulations. 
The Principal Investigator will assure that no deviation from, or changes to the protocol will take place 
without prior agreement from the sponsor and documented approval from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants. All personnel 
involved in the conduct of this study have completed Human Subjects Protection Training. 
 

Protocol Summary 
Title 
A pilot, proof of concept, placebo-controlled, parallel study of the effects of 
high dose intranasal oxytocin for the treatment of tinnitus 
Short Title 
High Dose Oxytocin Nasal Spray for Treatment of Tinnitus  
Brief Summary 
The purpose of this study is to evaluate the effects of high-dose intranasal 
oxytocin for treating tinnitus. The hypothesis is that high dose intranasal 
oxytocin can significantly reduce tinnitus severity and disability. 
Methodology 
Pilot, proof of concept, randomized, placebo-control, parallel study 
Endpoint 
The primary efficacy endpoint is the area under the VAS curve from baseline 
for all randomized participants during the blinded study phase. The 
secondary endpoint, which is exploratory, will be improvement (p < 0.10) in 
the Tinnitus Handicap Inventory Severity Scale (THI)/Clinical Global 
Impression Scale (CGI) and Tinnitus Functional Index (TFI). 
Study Duration 
Time from when the study opens to enrollment until completion of data 
analysis will be approximately 1 year. 
Participant Duration 
Participant participation will last approximately 4 months and involve about 17 
visits. 
Duration of IP 
administration 
Investigational product administration will last 15 weeks. The first 9 weeks of 
this period will involve the administration of active study medication to all 
participants. During the last 6 weeks, participants will be randomized to 
receive either placebo or active study medication for the remainder of the 
study. 
Population 
We will recruit patients from NYU Langone Medical Center’s Departments of 
Otolaryngology and Neurology. Eligible individuals will be age 18 to 75 with 
continuous perception of tinnitus for > 6 months, with a normal ENT 
evaluation within the past year. 
Study Sites 
NYU Langone Medical Center 
Number of participants 
50 participants expected to be enrolled with a goal of 30 study participants 
remaining after accounting for screen failures and participants who withdrew 
from the study. 
Description of Study 
Agent/Procedure 
The investigational product, oxytocin nasal spray (45 units/0.1mL for 100mL) 
is composed of: oxytocin 10 unit/MG/mannitol trituration (4.500g), magnesium 
chloride crystals (6.080g), citric acid anhydrous gran. (0.284g), sodium citrate 
powder (5.660g), sterile water for irrigation (100.000mL), and Pcca Mucolox 
liquid base (10.000mL). The dose for the oxytocin nasal spray will range from 
30 to 45 IU per puff to be administered four times per day, for an equivalent 
to 120 to 180 IU oxytocin/day. 
Reference Therapy 
The investigational product will be compared to placebo, a nasal spray 
consisting of magnesium, chloride crystals, citric acid anhydrous gran., 
sodium citrate powder, sterile water for irrigation, and Pcca Mucolox liquid 
base.  
Key Procedures 
Oxytocin (or placebo) will be self – administered by the study participants daily. 
Study visits will occur every two weeks, from prior to the baseline week to 15 
weeks after baseline, during which patients will be asked to rate the loudness 
of their tinnitus (VAS scale) and complete the THI questionnaire. Additional 
questionnaires and urinalysis will be performed at every study visit to monitor 
sodium levels and osmolality. 
Statistical Analysis 
The primary analysis is to provide an estimate of the partial eta squared effect 
size difference between placebo and treatment during the blinded phase of the 
study as well as to provide initial efficacy, safety and tolerability estimates 
during the initial open label study phase.    
 

Double Blind Phase 
Half of participants will receive 
active oxytocin nasal spray. Half 
will receive placebo. 
Schematic of Study Design 
 
 
Screening and 
Enrollment 
 
 
 
 
Beginning of 
Week 1 
 
 
 
 
 
End of Week 1 
through Week 9 
 
 
 
 
 
 
 
 
 
 
Week 10 through 
Week 15 
 
 
N = 50:  Obtain informed consent. Screen potential participants by inclusion and 
exclusion criteria; document. 
Baseline Period 
No changes in concomitant medications. Daily tracking of tinnitus loudness  
Non-blinded Phase 
All participants receive active 
oxytocin nasal spray.  

1 Key Roles 
Primary investigator:  
Lawrence Newman, MD 
NYU Langone Medical Center 
555 Madison Avenue, 3rd Floor 
New York, NY 10022 
(646)754-2000 
Lawrence.Newman@nyulangone.org  
 
Sub-investigator (Headache Fellow): 
Alison Thaler, MDNYU Langone Medical Center 
555 Madison Avenue, 3rd Floor 
New York, NY 10022 
(646)754-2000 
Alison.Thaler@nyulangone.org 
 
Research Coordinator, Regulatory Specialist, Data Management, and Primary Contact: 
Jacqueline Okolie, MD 
NYU Langone Medical Center 
555 Madison Avenue, 3rd Floor 
New York, NY 10022 
(646)754-2000, ext. 42035 
Jacqueline.Okolie@nyulangone.org 
2 Introduction, Background Information and Scientific Rationale 
2.1 Background Information and Relevant Literature 
Tinnitus, the perception of noise in the absence of an external stimulus, is a common, disabling and poorly 
understood phenomenon. Population based studies estimate the prevalence of tinnitus in the United States 
to range from 8-23%; in other countries, rates of 5-30% have been reported. In a recent study of adults 
experiencing tinnitus in the preceding 12 months, it was estimated that 1 in 10 Americans are affected.  
Fifty-six percent had lived with tinnitus for at least 5 years and 27% had symptoms for more than 15 years. 
Strikingly, 35% of respondents had nearly continuous tinnitus.  More than 7% reported that they considered 
their tinnitus to be a big or very big problem; which would suggest that 15 million Americans are significantly 
affected (1). Chronic tinnitus affects approximately 50 million Americans and yet there is currently no FDA-
approved first-line treatment for the condition. 
 
Tinnitus is generally divided into two categories: objective and subjective. Objective tinnitus is defined as 
tinnitus that is audible to another person, often as a result of turbulent blood flow, or muscle or palatal 
contractions, whereas subjective tinnitus, the most common subtype, is perceived only by the patient and 
usually occurs in the absence of an acoustic etiology (2). 
 
Originally believed to be an otolaryngologic disorder, recent studies suggest that, in fact, tinnitus is most 
likely a neurological disorder. Tinnitus is often the result of alterations within parts of the auditory pathways. 
This pathway encompasses the cochlea in the periphery transiting to the midbrain and terminating in the 
auditory cortex. Damage to the cochlea produces alterations in neuronal activity in which both cortical and 
subcortical projections adjust to the lack of output with ensuing changes in neural plasticity. These changes 
in neuroplasticity result in neuronal hyperactivity at various sites in the auditory pathway (dorsal cochlear 
nucleus, inferior colliculus, auditory cortex, and the striatum) and ultimately reorganization of the auditory 
tonotopic map (3).   
 
Outside of the auditory pathways, changes are also noted in the limbic system in patients with chronic 
tinnitus.  These changes are not surprising as there are numerous reports attesting to the emotional and 
affective comorbidities of tinnitus (4). Imaging studies reveal increased activation in the auditory cortex and 
amygdala in patients with tinnitus and psychological distress (5).   

 
Oxytocin, a 9-amino-acid neuropeptide, is produced by the magnocellular neurons of the hypothalamus, 
stored in the posterior pituitary and released into the bloodstream from the posterior lobe of the pituitary 
gland. Oxytocin plays a role in parturition and lactation, sperm transport and ejaculation, and has been 
shown to promote social bonding and other pro-social interactions. It is also believed that oxytocin may 
modulate human fear and anxiety responses (6). 
 
Parenteral administration of oxytocin has long been used for the initiation of labor as well as to control 
postpartum bleeding.  Parenteral oxytocin must be administered in hospital settings with careful monitoring.  
As oxytocin is structurally and functionally related to vasopressin, it can have a direct antidiuretic properties.  
Oxytocin has direct renal antidiuretic action by binding to vasopressin and oxytocin receptors in the kidney.  
When infused at high doses (> 20mU/min), there is a potential for oxytocin cross-reactivity with vasopressin 
which could result in water retention and a dilutional hyponatremia.  This risk is increased when oxytocin is 
intravenously administered with D5W or when high dose infusion protocols are used (7). Acute pulmonary 
edema following the use of oxytocin during cesarean section together with other oxytocic drugs has been 
reported as a rare complication of treatment. (8, 9, 10). Additionally, aqueous oxytocin is heat sensitive and 
therefore requires refrigeration to maintain potency. To combat this drawback, Milewski et al. studied the 
stability and absorption of an intranasal dry-powder formulation of oxytocin that did not require refrigeration 
(11). In this animal study, using cynomolgus monkeys, that have a similar nasal morphology as humans, 
the authors found that the intranasal route of administration had an approximately 12% relative 
bioavailability compared with intramuscular dosing.  
Intranasal application of oxytocin offers clinicians and patients a noninvasive alternative. The nasal cavity 
allows for the oxytocin to gain access to the brain by crossing the blood brain barrier in small yet biologically 
relevant amounts (12). Intranasal administration has been shown to raise CSF and serum levels of oxytocin 
in animal and human studies (13). 
 
Intranasal administration of oxytocin has also been shown to reduce fear through its action on the 
amygdala, and could therefore play a role in its lessening the distress caused by tinnitus (14). Predicated 
upon the above findings of the pathophysiologic underpinnings of tinnitus, the potential interactions of 
oxytocin on some of these brain regions and a recent publication by Marlin et al documenting the ability of 
oxytocin to modulate the inhibitory function of the auditory cortex, Azevedo et al conducted a pilot study to 
evaluate the effect of low-dose oxytocin on tinnitus intensity and distress in patients who had subjective, 
continuous tinnitus of at least 6 months duration (5, 15). They found that daily use of 16 IU of oxytocin 
reduced tinnitus-related handicap (THI) scores and to some extent, improved tinnitus distress. These 
investigators, in this pilot study, or others to our knowledge, have never increased the daily dose above 16 
IU. 
 
Based on their findings, I employed a similar strategy to treat two patients with tinnitus in the NYU Langone 
Medical Center Department of Neurology. In both patients, I initially instituted treatment as per the Azevedo 
et al trial, with 16 IU of oxytocin daily (1 spray containing 4 IU oxytocin in each nostril twice daily). Both 
patients noted tinnitus loudness was mitigated after a spray, and that after approximately 2 weeks, the 
tinnitus intensity was reduced.  Based on these reports, and while monitoring serum electrolytes, the dose 
of oxytocin was gradually increased every 4 weeks. I had oxytocin nasal spray compounded so that each 
spray was equal to 15 IU. At a dose of 30 IU (1 spray in each nostril) BID both patients reported a significant 
reduction in tinnitus intensity. At this dose, Patient 1 reported that his tinnitus lessened but gradually built 
in intensity until his next dose later that evening. 
Based on the partial benefit experienced by the patients, I hypothesized that the dosing paradigm was 
inadequate and increasing the dose and/or frequency of dosing could increase the duration of symptom 
improvement. This hypothesis is supported in the literature. 
 
Because the very short plasma half-life of nasally administered oxytocin (3-17 minutes), it was possible that 
the twice daily dosing employed by Azevedo et al. was insufficient to produce a sustained and  meaningful 
relief of tinnitus (16). Reviewing the literature, I found that most studies that employed oxytocin nasal spray 
used once or twice daily dosing at low doses, because that was what had been utilized in past studies 

without producing serious adverse events. Nearly every study concluded that studies employing higher 
doses should be attempted in the future. 
 
MacDonald et al. reviewed the safety and side effects of intranasal oxytocin in human studies (17). They 
reviewed 38 randomized controlled trials conducted over a 20 year period, involving 1529 subjects.  These 
studies used doses from 18-40 IU in doses ranging from once daily to 4 times daily. Most of the participants 
in the studies (76%) were healthy adults 20-30 years old. Of the 1529 study participants, 926 received 
oxytocin. Importantly, of the 1529 participants, mild side effects were reported by 18%.  The main categories 
of side-effects included: feeling more calm, relaxed or comfortable, or having more energy (5%), 
drowsiness, lightheadedness or headaches (6%), and nasal irritation, dryness of the mouth or throat (3%).  
Importantly, there was a nearly 1:1 relationship between the frequency of side-effects reported in the active 
and placebo arms. A Wilcoxon signed rank test found no significant difference between the frequency of 
side-effects reported for oxytocin or placebo. 
 
Although the majority of the studies employed low dose or single doses of oxytocin nasal spray, 2 studies 
employed 40 IU QID for one week, and 1 study used 40 IU BID over 13 weeks. That long term, double-
blind, placebo-controlled trial studied the effects of high-dose oxytocin nasal spray in 59 women with chronic 
constipation (18). Twenty-nine women received oxytocin; the authors reported no changes in blood 
pressure or electrolyte concentrations in either study arm.  Five woman reported menstrual irregularities (1 
with oxytocin, 4 receiving placebo). Eleven in the oxytocin group and 12 subjects in the placebo group 
reported mild side-effects consisting of headache, nausea, abdominal pain, weight gain and nasal irritation. 
The authors found no significant differences between treatment with oxytocin or placebo, and concluded, 
“the short half-time of oxytocin, in combination with only two administrations daily, might explain the 
absence of effects on constipation in our study.”   
 
Many of the studies of intranasal oxytocin as treatment for a variety of psychiatric disorders in humans were 
underpowered (19). Clinical trials of oxytocin nasal spray have employed dosages ranging from 15 IU to 
more than 7000 IU (20).  Den Boer and Westenberg, in a double-blinded, placebo-controlled study of 12 
patients with obsessive-compulsive disorder (OCD), employed 40 IU oxytocin QID for 6 weeks.  There were 
no changes in blood pressure or weights; in the placebo group, one patient complained of headache and 
in the oxytocin group, four patients had mild dizziness, and two patients reported dry mouth and mild 
headache. Additionally, they reported in this paper that they gave 2 patients a threefold higher dose, without 
producing side-effects.  High doses of intranasal oxytocin were assessed in 7 patients with OCD; 5 received 
160 IU daily and 2 with 320 IU daily. The authors reported there were no significant changes in blood 
pressure, pulse, or serum osmolality and “side effects were minimal” but not detailed (21).  Although this 
study employed much higher doses than were previously studied in OCD, the treatment phase only lasted 
one week and failed to show any significant differences between the active and placebo arms.  Here too 
the authors noted that the failure to obtain therapeutic efficacy may have been due to the short period of 
drug administration and that “even at high doses, a week of intranasal oxytocin administration does not 
sufficiently effect the CNS to result in a change in behavior.” 
 
Four case reports (5 patients) of adverse reactions to oxytocin nasal spray were identified through an on-
line literature search.  One was of a 55 year old man with OCD treated with daily doses of oxytocin 8.4-
16.8 IU administered 3 times daily over 4 weeks who developed psychotic symptoms and memory loss 
associated with low plasma sodium and osmolality (22). Two patients using intranasal oxytocin to facilitate 
lactation developed severe water intoxication; both patients were using “excessive self-administrations” of 
oxytocin, one was receiving large amounts of intravenous fluid during an in-patient admission for a viral 
illness, the other was drinking  5 liters of herbal tea daily (23). Two patients given oxytocin intranasally 40 
IU QID for a week and saline placebo for a week to treat trichotillomania had no significant changes in blood 
pressure and pulse measurements.  One patient reported one day of increased anxiety, and the other slight 
nasal irritation, both while taking placebo (24).  
 
While there is no evidence in the literature of the intranasal formulation of oxytocin specifically causing 
pulmonary edema, one of the participants enrolled into our study, has experienced this adverse event on 

the 40 IU four times daily dose. After 11 days at this dose, he noticed shortness of breath and decreased 
exercise tolerance.  His chest x-ray and subsequent CT was consistent with mild pulmonary edema. 
 
Although no longer available in the United States, intranasal oxytocin is marketed in several European 
countries to improve lactation.  Product information from the Netherlands noted that headaches, nausea 
and allergic dermatitis occurs rarely (>1/10,000, <1/1000), and abnormal uterine contractions may occur at 
times (>1/100, <1/100) (17).  As detailed in the report of Hubner-Mayer, prolonged use of excessive doses 
together with large volumes of fluid has been linked to water intoxication with hyponatremia. The patients 
reported were self-medicating at doses significantly higher than will be employed in our study. This rare 
adverse reaction of water intoxication with oxytocin usage is probably the result of similarities between 
oxytocin and vasopressin, which acts as an anti-diuretic.  
 
In reviewing the published reports employing oxytocin nasal spray as treatment for a variety of medical and 
psychiatric conditions, which includes several hundred subjects, there have been no reports besides the 
ones mentioned above, who have developed pulmonary edema. Additionally, we have treated 14 patients 
in our study without this adverse event, and 3 of my patients have received high dose intranasal oxytocin 
for 2 years, without evidence of laboratory abnormalities, or complaints of shortness of breath. 
For the above reasons, I believe that the risk of pulmonary edema (our case would be the only reported 
who did not have co-existent fluid overload that was either self-inflicted or occurred with iatrogenic 
intravenous fluids overload) is exceedingly low and therefore does not increase risk or decrease the 
acceptability of the risk, and should allow for a continuation of an IND Exemption. 
 
Since the literature supported the relative safety of using higher doses, I decided to change the dosing in 
both of my patients, while monitoring serum electrolytes. 
 
In patient 1, increasing the frequency to 30 IU (2 sprays in each nostril) TID reduced the intensity of the 
tinnitus for longer periods of time, but the intensity continued to increase before the next dosing period. 
Ultimately, increasing the dosing to 45 IU (3 sprays) TID and then QID produced a dramatic and sustained 
improvement. His THI was reduced from 96 (catastrophic) to 16 (mild or no handicap); his tinnitus loudness 
decreased from 9-10/10 to 3-4/10, but more importantly, at the higher dose, his 2 year constant, unremitting 
tinnitus improved so that the perception of noise is present on only 6 or 7 days per month. He has no tinnitus 
on the other days. Unfortunately, the patient complained that his nostrils would drip for up to 30 minutes 
after each dose, which was not only embarrassing but made it difficult to ascertain if the entire dosage was 
being administered and absorbed. To simplify the dosing regimen, I had the spray reformulated so that 
each spray contained 45 IU and had a non-drip additive, Pcca Mucolox, added to the bottle. On 3 occasions, 
he was unaware that his medication was improperly stored, and each time, tinnitus recurred within 24 hours. 
 
Patient 2’s scores were reduced to a significant but lesser extent because the patient is unable to dose 4 
times daily as instructed. Nonetheless, at 45 IU BID his THI decreased from 75 (severe handicap) to 18 
(mild handicap) and tinnitus loudness decreased from 7/10 to 4/10 but remains constant. Neither patient 
experienced significant adverse effects or changes in their vital signs or serum sodium levels. Patient 2 
occasionally reports burning in his nostrils. 
 
We postulate that long term treatment with high-dose oxytocin may reduce the frequency and severity of 
tinnitus, the burden tinnitus symptoms cause patients, and improve their quality of life. However, since the 
2 patients were treated with oxytocin compounded as 15 IU per spray, and doses were increased by 15 IU, 
I cannot be certain that a dose between 30 IU QID, the dose at which both patients initially reported 
improvement, and 45 IU QID, the dose that produced significant improvement, may have produced similar 
benefit. 
 
The study will be conducted in compliance with the requirements for institutional review set forth in part 56 
and within the requirements for informed consent set forth in part 50, and the investigation will be conducted 
in compliance with the requirements of 312.7. 

2.2 Name and Description of the Investigational Agent  
The investigational product is an oxytocin nasal spray composed of: oxytocin/MG/mannitol trituration, 
magnesium chloride crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for 
irrigation, and Pcca Mucolox liquid base.  
 
The placebo nasal spray consists of magnesium chloride crystals, citric acid anhydrous gran., sodium 
citrate powder, sterile water for irrigation, and Pcca Mucolox liquid base. Both placebo and active drug will 
be handled and stored the same way, in amber glass bottles and kept between 36°F to 46°F (2°C - 8°C).   
 
We believe this study meets the criteria for IND Exemption for the following reasons: 
Oxytocin has been tested and is approved by the FDA in different indications. This will be a proof of concept 
study only, and therefore it is not intended to be reported to the FDA in support of a new indication.  If this 
pilot study, proof of concept study, is successful, we plan to initiate a large-scale study that would then be 
used to support a new indication, requiring IND application.  
 
We do not intend to use the results of this study to support any change in the advertising of this product 
and are not affiliated with any sponsors that carry vested interest in the commercial presentations of 
oxytocin. 
2.2.1.1 Clinical Data to Date 
See background data in Section 2.1. 
2.2.1.2 Dose Rationale (if applicable)  
Although the route of administration (nasal spray) used in this study differs from the currently parenteral 
administration, nasal spray applications of oxytocin have been previously employed for a number of 
different medical and psychiatric conditions as well as in healthy controls for more than a decade. A recent 
meta-analysis detailed these studies in which doses of oxytocin ranged from 15 to more than 7000 IU were 
given without significant adverse events (20). Additionally, recommendations for the standardization of 
oxytocin nasal administration and guidelines for its reporting were published in the past decade (25).  The 
authors stated “Transmucosal nasal delivery provides a non-invasive alternative route for drugs with poor 
systemic bioavailability after oral administration. Intranasal administration causes minimal discomfort for 
the patient, is simple to use, and typically results in high compliance.” 
 
Although this study will use a dosage of oxytocin that is higher than used in a previous study of tinnitus (45 
IU QID vs 8 IU BID), it is well within the dose range reported in other studies in the psychiatric literature. In 
those studies, adverse events were rare, non-life threatening and fully reversible. 
 
Additionally, oxytocin nasal spray has been reported in other studies to be very safe (17). 
  
We therefore believe that neither the route of administration nor dose employed in this study would 
significantly increase the risks (or decrease the acceptability of the risks) associated with the use of the 
drug product. 
2.3  Rationale 
The hypothesis is that high dose intranasal oxytocin can significantly reduce tinnitus severity and disability. 
We hypothesize that treatment with high dose oxytocin nasal spray will result in a significant improvement 
of tinnitus loudness as measured by VAS when compared to placebo. 
 
Relatively high rates of placebo response have been seen in several studies of tinnitus. As in other 
subjective symptoms, such as pain and affect, short term improvement after placebo can be meaningful. 
Therefore, the need of run in phase to determine the true response rate to the active intervention. 

2.4 Potential Risks & Benefits 
2.4.1.1 Known Potential Risks 
Greater than minimal risk. Due to the risk of uterine contractions associated with oxytocin use, female 
subjects of childbearing potential will be instructed to use a double barrier of birth control and the PI will 
discuss with them the potential dangers if they were to become pregnant while using the drug. It is possible 
that high dose oxytocin may cause recruitment of vasopressin leading to a decrease in plasma and an 
increase in urine osmolality and a decrease in serum sodium levels. As a result, there is the less common 
risk of developing acute pulmonary edema. The main categories of side-effects include: feeling more calm, 
relaxed or comfortable, or having more energy (5%), drowsiness, lightheadedness or headaches (6%), and 
nasal irritation, dryness of the mouth or throat (3%).  Patients with any serious adverse events will be 
immediately withdrawn from the study. However, because of the extremely short half-life of oxytocin, any 
adverse event would not be expected to be long-lasting. 
 
There is the possibility of bruising from the needle site after blood draws at scheduled visits. 
 
Subjects will be monitored with regular communication to note study challenges or adverse events. 
Individuals will work with study personnel who have been appropriately trained and access to data will be 
limited to an as needed basis. Information linking the linkage codes to participant’s names, medical record 
numbers, and social security numbers will be stored in a secure location separate from the medical 
information and only accessible to members of the study team when needed, after approval by the NYU 
School of Medicine IRB and Principal Investigator. This access will be documented. 
2.4.1.2 Known Potential Benefits 
Subjects may or may not directly benefit from being in the study. Close medical monitoring of their 
symptoms may be a potential benefit if subjects are seen infrequently otherwise. Furthermore, if the 
medication is effective for tinnitus, participants may indeed improve. However, the overall benefit of 
participating in this research is that it may help others with tinnitus in the future. 
3 Objectives and Purpose 
The purpose of this study is to evaluate the effects of high-dose intranasal oxytocin for treating tinnitus. 
  
The primary outcome measurement will be a change in the VAS at 3 timepoints: 
1. Comparative endpoint of VAS of all 30 subjects at 9th week of treatment with active drug vs baseline. 
2. Comparative endpoint during the cross-over phase of VAS at the 17th visit (15th week of study) between 
the 15 subjects who received placebo vs the 9th week of the non-blinded phase for the same subjects 
(when they were on active drug). This endpoint compares the 15 patients that were switched from active to 
placebo and compares their response on placebo (from the double blind phase) with their response on 
active drug (from the non-blinded phase) and compares them to the 15 subjects that remained on active 
drug during the entire study. 
3. A parallel group analysis where we compare both arms in the last week of the double-blind phase—so 
in essence we are comparing those 15 who were on active throughout the entire study to those that started 
on active and changed over to placebo. 
 
Secondary endpoints of interest are also defined a-priori: 
1. A change in the THI by at least one grade contrasting the 9th week (end of the single blinded phase) and 
the 15th week of the study (end of the double blinded phase) between the 15 subjects who were switched 
from active drug to placebo.  
2. A change in the THI by at least one grade during the last 2 weeks of the double-blind stage (weeks 14 
and 15 of the study contrasting those on active drug vs. placebo. 
 
Exploratory endpoints of interest include: 
Clinical Global Impression (CGI) measured following the same approach of the primary endpoints. 
Tinnitus Functional Index (TFI) measured following the same approach of the primary endpoints. 

3.1 Primary Objective 
To significantly improve tinnitus loudness as measured by VAS, when using intranasal oxytocin compared 
to placebo. 
4 Study Design and Endpoints 
4.1 Description of Study Design 
This is a pilot, proof of concept, placebo-controlled, parallel study. Participants will be recruited from NYU 
Langone Medical Center’s ENT Department and will receive either high-dose intranasal oxytocin or the 
placebo, a nasal spray containing the same inactive ingredients as the active drug: magnesium chloride 
crystals, citric acid anhydrous gran., sodium citrate powder, sterile water for irrigation, and Pcca Mucolox 
liquid base to replicate the feel and consistency of the oxytocin nasal spray. When changing the 
compounding pharmacy, we conducted a blinded test of placebo formulations. We found that the placebo 
containing all of the inactive ingredients as the active oxytocin nasal spray was a significantly better match 
in consistency to the active drug, as compared to distilled water and Pcca Mucolox. The primary outcome 
measure for this study will be a greater than 50% improvement in tinnitus loudness on the Visual Analog 
Scale (VAS). The secondary outcome measure will be improvement (p < 0.10) in the Tinnitus Handicap 
Inventory Severity Scale (THI)/Clinical Global Impression Scale (CGI) and Tinnitus Functional Index (TFI) 
(26, 27, 28). The metrics on the secondary endpoints are exploratory only and as such we will not look for 
specific changes. These results will guide us in the next, larger study.  
 
The study will consist of 3 phases: 
1. A 1 week baseline phase during which time we will track daily tinnitus loudness on VAS using a 
study log. Patients will not receive any study drug during this phase. No changes in any 
concomitant medications will be allowed during this phase. In addition, the use of dinoprostone or 
ephedrine is not permitted throughout the study. 
2. A 9 week non-blinded phase is which all patients will receive the oxytocin nasal spray 4 times 
daily. All patients will begin at a dose of 30 IU 4 times daily for 2 weeks; If no response is reported 
(defined as a decrease in VAS of < 2), they will have the dose increase by 5 IU per spray every 2 
weeks, until a maximum dose of 45 IU 4 times daily. If patients report improvement (defined as 
improvement in VAS >3) at any dose, they will remain at that dose through the end of the second 
phase. In the event that the patient experiences a moderate side effect, the dose will be 
decreased to the previous dose for the remainder of this phase. 
3. A 6 week double-blinded phase in which half of the participants will receive oxytocin nasal spray 
and half will receive placebo nasal spray. Neither the PI nor subject will know which drug they are 
receiving. However, the study coordinator will have access to this information as required to 
assign the medications. 
Patients will come to the Preston Robert Tisch Center for Men’s Health for study visits every 2 weeks and 
be administered the VAS and THI/CGI scales by the research coordinator or principal investigator. The 
screening visit will be the most comprehensive and include obtaining informed consent, a physical exam 
with vital signs, laboratory studies, questionnaires, an ECG, and review of medical and medication history 
to confirm all inclusion criteria are met and that there are no exclusion criteria present. During these visits 
they will have urine testing for sodium and osmolality. Every other week, they will receive a phone call from 
study staff to discuss their experience using the study drug and monitor for any adverse effects. They will 
complete the Tinnitus Functional Index questionnaire over the phone as well. When the subjects come in 
for their study visit, 4 weeks after the baseline period, they will receive enough study medication for the rest 
of the study, to allow for randomization to placebo or active drug at that time. 

4.2 Study Endpoints 
4.2.1.1 Primary Study Endpoints 
The primary outcome measurement will be the collective area under the Visual Analog Scale (VAS) curve 
above the week 3 baseline as assessed from week 3 to week 6 of the double blinded study phase.   
4.2.1.2 Secondary and Exploratory Study Endpoints 
Secondary endpoints will consist of safety and tolerability metrics including adverse event incidence and 
severity, regimen adherence and voluntary study drop-out rates reported during the non-blinded and 
blinded study phases.  The frequency and percentage of each secondary measure will be determined for 
the non-blinded study phase and by study arm for blinded study phase.  Additionally, any changes in THI 
greater than 1 grade will be determined from week 3 to week 6 of the double blinded study phase. The 
frequency and percentage of these changes will be summarized by study arm.    
 
A descriptive summary using means and standard deviations stratified by dosage group for the treatment 
subgroup during the blinded study phase will be performed. The partial eta squared effect size difference 
will be estimated. 
5 Study Enrollment and Withdrawal 
Patients older than 18 years old are able to participate. The maximum age of participants is 75 years old. 
The racial and ethnic origin will reflect the demographics of the populations that seek evaluation of tinnitus 
at NYU Langone Medical Center.  
5.1 Inclusion Criteria 
In order to be eligible to participate in this study, an individual must meet all of the following criteria: 
1. Age ≥18 years 
2. Continuous perception of subjective tinnitus for ≥ 6 months duration 
3. Evidence of a normal otolaryngologic evaluation within the past year with no evidence of otitis 
media or externa 
4. THI of > 16  
5. Tinnitus loudness rating of >4/10 
5.2 Exclusion Criteria 
An individual who meets any of the following criteria will be excluded from participation in this study: 
1. Treated for tinnitus < 6 months due to the acute nature of their condition and slight handicap 
according to the Tinnitus Handicap Inventory Severity Scale.  
2. Tinnitus of a muscular or vascular etiology  
3. Conductive hearing loss 
4. History of migraine 
5. History of pulmonary edema 
6. History of congestive heart failure 
7. History of severe renal disease 
8. Prior use of oxytocin nasal spray 
9. Latex allergy 
10. Women who are currently breastfeeding 
11. Pregnancy 
 
Because tinnitus may be co-morbid with migraine, and because migraine may be responsive to treatment 
with intranasal oxytocin, patients who suffer from migraines will be ineligible to participate. As patients 
who are allergic to latex may react to the oxytocin spray, individuals with this allergy will be ineligible to 
participate in the study. 

5.3 Vulnerable Subjects 
Prisoner-patients will not be approached for participation due to federal and state requirements governing 
participation of prisoners in research. Pregnant women and individuals with impaired decision-making 
capacity also will not be approached for this study.  
5.4 Strategies for Recruitment and Retention 
We will recruit patients from NYU Langone Medical Center’s Departments of Otolaryngology and 
Neurology. We will aim to recruit and enroll 50 patients with a goal of 30 study participants remaining after 
accounting for some screen failures. Subjects will be identified for study inclusion through otolaryngologists’ 
and neurologists’ referrals of patients with tinnitus.  
 
An IRB-approved dear provider letter will be sent to providers from NYU Departments of Otolaryngology 
and Neurology to assist in identifying potential study participants for referral to the study team. A member 
of the study team will contact the individual for screening for the study. Data including patient initials, age, 
date of birth, menstrual status (if applicable), allergies, prior history of migraine, tinnitus quality, severity, 
duration, ENT evaluation, and current medications will be used for subject identification, informing subjects, 
and initial discussion of subject eligibility. Information will be obtained through review of medical records 
and direct interview. The Principal Investigator will review the informed consent form with the potential 
participant. The Principal Investigator and Research Coordinator will have access to identifiable information 
as needed for recruitment of study participants. Emails will be securely sent to potential participants via 
send safe.  
5.4.1.1 Use of DataCore/Epic Information for Recruitment Purposes 
This study will utilize EPIC to identify subjects. The PI and Research Coordinator will have access to the 
EPIC search results. 
 
Any recruitment information sent by email will utilize Send Safe email.  
 
Once potential subjects have been identified, the study team will notify the treating physician (TP) that 
they have patients eligible to participate as follow:  
• 
TP has been notified that the study team will contact potential subjects directly, by letter, phone, 
email, or the MyChart portal etc. 
 
Once contact is made, approved recruitment language will be used to communicate the reason they are 
being contacted and subjects will be asked if they are interested in participating in this specific study. 
Should the potential subjects agree, the study team will provide the subjects with information regarding 
the next steps for participation.  
 
If a subject requests information regarding opting out of further recruitment for all research, subjects will 
be directed to contact research-contact-optout@nyumc.org or 1-855-777-7858. 
5.5 Duration of Study Participation 
The study will last about 4 months and will involve about 17 visits. This includes the consenting process, 
screening procedures and all study visits.  
5.6 Total Number of Participants and Sites  
Recruitment will end when approximately 50 participants are enrolled. It is expected that approximately 
50 participants will be enrolled in order to produce 30 evaluable participants. These participants between 
the ages of 18 and 75 are to be entered into this study at NYU Langone Medical Center. This research 
project will only be taking place at this site. This study will be an out-patient study. The study visits will be 
at the NYU Langone Preston Robert Tisch Center for Men's Health, 555 Madison Avenue, 3rd Floor, New 
York, NY 10022. 

5.7 Participant Withdrawal or Termination 
5.7.1.1 Reasons for Withdrawal or Termination 
Participants are free to withdraw from participation in the study at any time upon request. An investigator 
may terminate participation in the study if: 
• 
Any clinical adverse event (AE) or other medical condition or situation occurs such that continued 
participation in the study would not be in the best interest of the participant 
• 
The participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation 
• 
At any point during the study, a subject is found to have abnormal urine sodium or osmolality levels 
or an abnormal comprehensive metabolic panel 
• 
They experience a significant rise in blood pressure (>150/100) or intolerable side effects (nausea, 
vomiting, headache, or significant worsening of tinnitus) 
5.7.2 Handling of Participant Withdrawals or Termination 
Subjects may withdraw from the study at any time. Subjects that choose to withdraw early from the study 
will be voluntarily surveyed for reasons for withdrawal. They will be asked for permission to continue to 
utilize the data collected up to the point of withdrawal for research purposes.  Should they decline, all data 
past the note of withdrawal will be deleted from the record system.  Subjects will be required to return any 
unused samples of nasal spray.   
We will reach out to those withdrawn or terminated participants or those who discontinue the study agent 
but remain in the study for follow-up via 3 phone calls to them. Should participants not respond to our 
phone calls, a certified letter will be sent to their home address. For those participants who withdrew 
because of AEs, we will try to continuously follow them until AEs resolve. 
 We plan to replace participants who withdraw or discontinue the study early, in order to collect the 
minimum data required to determine the efficacy of the study drug, per Section 9.3 of the Statistical 
Considerations for the study, Analysis Datasets.  
5.8 Premature Termination or Suspension of Study 
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause. Written notification, documenting the reason for study suspension or termination, will be provided 
by the investigator to the IRB. If the study is prematurely terminated or suspended, the PI will promptly 
inform the IRB and will provide the reason(s) for the termination or suspension. 
Circumstances that may warrant termination or suspension include, but are not limited to: 
• 
Determination of unexpected, significant, or unacceptable risk to participants  
• 
Demonstration of efficacy that would warrant stopping 
• 
Insufficient compliance to protocol requirements 
• 
Data that are not sufficiently complete and/or evaluable 
• 
Determination of futility 
 
Study may resume once concerns about safety, protocol compliance, data quality are addressed and 
satisfy the IRB. 
6 Study Agent   
6.1 
Study Agent(s) and Control Description 
The investigational product, oxytocin nasal spray (45 units/0.1mL for 100mL) is composed of: oxytocin 10 
unit/MG/mannitol trituration (4.500g), magnesium chloride crystals (6.080g), citric acid anhydrous gran. 
(0.284g), sodium citrate powder (5.660g), sterile water for irrigation (100.000mL), and Pcca Mucolox liquid 
base(10.000mL). 
See Oxytocin Nasal Spray package insert (29).  
 

The placebo nasal spray consists of: magnesium chloride crystals (6.080g), citric acid anhydrous gran. 
(0.284g), sodium citrate powder (5.660g), sterile water for irrigation (100.000mL), and Pcca Mucolox liquid 
base (10.000mL). Both placebo and active drug will be handled and stored the same way.  
6.1.1 
Acquisition 
The study agent and placebo will be prepared and acquired from VLS Pharmacy/New Drug Loft. They will 
be shipped to the study site at the Center for Men’s Health, 555 Madison Avenue, 3rd Floor, New York, NY 
10022. 
6.1.2 
Formulation, Appearance, Packaging, and Labeling 
This nasal spray will be a liquid prepared at VLS Pharmacy/New Drug Loft and contained in 30mL amber 
glass bottles with nasal sprayers. Both active drug and the placebo will appear identical in the glass bottles. 
These bottles will be labeled with subject specific labels to be marked by the study coordinator. The label 
will also say “Oxytocin/Placebo.” This study medication is investigational and will be formulated specifically 
for the purpose of meeting the trial plan.  
6.1.3 
Product Storage and Stability 
Study agent and placebo will be stored in amber glass bottles in a secure refrigerator that only study 
personnel will have access to. The medications will be kept between 36°F to 46°F (2°C - 8°C). They cannot 
be frozen or exposed to direct light. After its preparation, the study agent is good for 30 days in the 
refrigerator. It must be kept out of the reach of children.   
6.1.4 
Preparation 
The study drug and placebo nasal sprays will be mixed/prepared by VLS Pharmacy/New Drug Loft and 
shipped to the study site. They can be contacted at (718)854-3061. 
6.1.5 
Dosing and Administration 
After the baseline period of the study (1 week), subjects will receive intranasal oxytocin for 9 weeks. They 
will receive a spray bottle with study medication at Visit 3 to be self-administered at home four times per 
day (9AM, 1PM, 5PM, and 9PM). They will be instructed to apply 1 puff (the equivalent of 30 to 45 oxytocin 
IU) in one nostril four times per day, equivalent to 120 to 180 IU per day.  
 
Subjects will be shown the proper way to use the nasal spray and administer the study medication. With 
their head facing forward, not tilted up or down, they should place the sprayer in one nostril and spray once 
while holding their breath. They should then pinch both nostrils closed for 5 seconds. They will be instructed 
not to sniff in or blow their nose for at least 5 minutes after administration. During the following 6 weeks of 
the study, subjects may receive placebo or oxytocin nasal spray. The placebo will be administered in the 
same manner as the active study drug, with 1 puff in one nostril four times per day (9AM, 1PM, 5PM, and 
9PM). If the subject is randomized to the active drug during this phase, their dose will be the same dose 
they received during Week 9 of the study, during the non-blinded phase. 
 
The nasal spray should be refrigerated when not being used. Subjects will also have a re-freezable bag to 
store their spray bottles in when not near a refrigerator.  
6.1.6 
Route of Administration 
The route of administration for the study medication is intranasally. 
6.1.7 
Starting Dose and Dose Escalation Schedule 
All subjects will begin at a dose of 30 IU 4 times daily for 2 weeks. If no response is reported (defined as a 
decrease in VAS of < 2), they will have the dose increase by 5 IU per spray every 2 weeks, until a maximum 
dose of 45 IU 4 times daily. If patients report improvement (defined as improvement in VAS >3) at any dose, 
they will remain at that dose through the end of the second phase. In the event that the patient experiences 
a moderate side effect, the dose will be decreased to the previous dose for the remainder of this phase. 

Subjects will be informed that depending on their responses, their dose may stay the same, be increased 
or decreased. Accordingly, after Visit 3, active drug will be dispensed at office study visits every 2 weeks 
during the non-blinded phase.  
 
The dose for the oxytocin nasal spray will be 30, 35, 40, or 45 IU per puff to be administered four times per 
day. This dosage was determined by treating 2 patients (as described above) with tinnitus in our clinical 
practice.  Both patients were initially treated with 16 IU oxytocin nasal spray daily as detailed in the Azevedo 
et al study (5). Both patients noted slight improvement, and over the course of several months the dose 
was gradually increased while following their clinical course and vital signs and laboratory studies. 
Maximum benefit was noted at a dose of 45 IU QID.  
6.1.8 
Dose Adjustments/Modifications/Delays 
As stated in Section 6.1.7, dose changes will be made according to subjects’ responses. Any subjects that 
experience moderate side effects will have their dose lowered to the previous dose for the remainder of 
that study phase. If a subject is found to have urine electrolyte (sodium) or osmolality abnormalities during 
study visits, study medication will be discontinued and the subject will have to withdraw from the study. 
6.1.9 
Duration of Therapy 
The study consists of 3 phases:  
1. 1 week baseline period during which no study medication will be administered.  
2. 9 week non-blinded phase during which all subjects receive oxytocin nasal spray (30 – 45 IU four 
times/day)  
3. 6 week “double-blind” phase during which half the subjects receive oxytocin nasal spray (up to 45 
IU four times/day) or the placebo nasal spray.  
6.1.10 Tracking of Dose 
Subjects will be asked to bring their study medication bottles in to each office study visit, every other week. 
They will also be asked to complete a daily tinnitus severity log that will also ask if they have taken each 
dose that day. 
6.2 Study Agent Accountability Procedures 
After the compounding pharmacy prepares and delivers the active drug and placebo, the study coordinator 
will have access to the secure refrigerator where study drug is stored. At Visits 3, 5, 7, and 9, she will 
distribute the study agent (oxytocin nasal spray) to each participant. The participants will receive only 
enough of the study agent for the next 2 weeks of the study. They will have to return to the office at weeks 
11 and 13 to receive study drug or placebo for the double blind phase of the study.  
 
Regular study drug reconciliation will be performed to document drug assigned, drug consumed, and drug 
remaining. This reconciliation will be logged on a drug accountability log, and signed and dated by the study 
team. 
 
Subjects will receive a phone call from the study coordinator to discuss the subject’s experience using the 
study drug the prior week. Subjects will also have to complete a daily log noting the severity of their tinnitus 
for that day and the time they took their medication. Study staff will review this information at each visit, 
every other week.  
7 Study Procedures and Schedule 
7.1 Study Procedures/Evaluations 
Patients will come to the Preston Robert Tisch Center for Men’s Health for study visits every 2 weeks and 
be administered the VAS and THI/CGI scales by the research coordinator or principal investigator. The 
screening visit will be the most comprehensive and include obtaining informed consent, a physical exam 
with vital signs, laboratory studies, questionnaires, an ECG, and review of medical and medication history 

to confirm all inclusion criteria are met and that there are no exclusion criteria present. During these visits 
they will have urine testing for sodium and osmolality. Every other week, they will receive a phone call from 
study staff to discuss their experience using the study drug and monitor for any adverse effects. They will 
complete the Tinnitus Functional Index questionnaire over the phone as well. When the subjects come in 
for their study visit, 4 weeks after the baseline period, they will receive enough study medication for the rest 
of the study, to allow for randomization to placebo or active drug at that time. 
7.1.1 
Study Specific Procedures 
Visit Details 
 
 
 
 
Visit 
Visit Type 
Procedures 
Labs 
Questionnaires 
 
Screening   
(Week 0) 
Office visit 
Obtain informed consent, 
review of medical and 
medication history, 
physical exam, vital signs, 
ECG 
Comprehensive 
metabolic panel, urine 
electrolytes & 
osmolality,           
urine pregnancy test 
X 
 
Baseline 
(beginning of  
Week 1) 
Phone 
Review of current 
medications, issue daily 
VAS log 
 
X 
Baseline 
End of Week 1 
Office visit 
Review of current 
medications, dispense 
active drug, review VAS 
log 
Urine pregnancy test 
X 
Non-Blinded 
Phase 
Week 2 
Phone 
Review of current 
medications 
 
X 
Week 3 
Office visit 
Review of current 
medications, study drug 
reconciliation, dispense 
active drug, study log 
review 
Urine electrolytes & 
osmolality, urine 
pregnancy test 
X 
Week 4 
Phone 
 
 
X 
Week 5 
Office visit 
Review of current 
medications, study drug 
reconciliation, dispense 
active drug, study log 
review 
Urine electrolytes & 
osmolality, urine 
pregnancy test 
X 
Week 6 
Phone 
Review of current 
medications 
 
X 
Week 7 
Office visit 
Review of current 
medications, study drug 
reconciliation, dispense 
active drug, study log 
review 
Urine electrolytes & 
osmolality, urine 
pregnancy test 
X 
Week 8 
Phone 
Review of current 
medications 
 
X 
Week 9 
Office visit 
Review of current 
medications, randomize & 
dispense new drug, study 
log review 
Urine electrolytes & 
osmolality, urine 
pregnancy test 
X 
Week 10 
Phone 
Review of current 
medications 
 
X 
 

Week 11 
Office visit 
Review of current 
medications, study drug 
reconciliation, dispense 
study drug, study log 
review 
Urine electrolytes & 
osmolality, urine 
pregnancy test 
X 
 
 
Double Blind 
Phase 
Week 12 
Phone 
Review of current 
medications 
 
X 
 
Week 13 
Office visit 
Review of current 
medications, study drug 
reconciliation, dispense 
study drug, study log 
review 
Urine electrolytes & 
osmolality, urine 
pregnancy test 
X 
 
Week 14 
Phone 
Review of current 
medications 
 
X 
Week 15 
Office visit 
Review of current 
medications, study drug 
reconciliation, study log 
review 
Comprehensive 
metabolic panel, urine 
pregnancy test 
X 
7.1.2 Clinical Laboratory Evaluations 
• 
Blood tests: Comprehensive Metabolic Panel (CMP) at the screening visit (as abnormal 
values will exclude patients from the study) and final study visit 
• 
Urinalysis: dipstick urinalysis, including electrolyte levels and urine concentration; if dipstick is 
abnormal, complete urinalysis with microscopic evaluation is required. 
• 
Pregnancy test, female subjects of childbearing potential will undergo a urine pregnancy test 
every week that an office study visit occurs. 
7.1.3 Specimen Preparation, Handling, and Storage 
Labeled urine samples will be taken the same day to the Tisch Laboratory for processing. Labels will 
include the participant’s initials, subject ID number, and date and time the sample was obtained. 
7.2 Study Schedule 
7.2.1 Screening  
Screening Visit  
• 
Obtain informed consent of potential participant verified by signature on written informed consent 
for screening form. 
• 
Review medical history to determine eligibility based on inclusion/exclusion criteria. 
• 
Review medication history to determine eligibility based on inclusion/exclusion criteria.  
• 
Obtain demographic information, alcohol and tobacco use history. 
• 
Perform medical examinations and ECG needed to determine eligibility based on 
inclusion/exclusion criteria. 
• 
Draw blood for CMP to determine eligibility. 
• 
Collect urine for electrolyte levels, urine osmolality, and pregnancy test if applicable. 
• 
Perform questionnaires including the Tinnitus Handicap Inventory (THI), Clinical Global Impression 
(CGI) for baseline, and suicidality history. 
o 
Due to the correlation between tinnitus and suicide, the investigator will evaluate suicidality 
history by patient interview to be recorded in the CRF. This will be re-assessed at follow 
up visits as a part of the THI. If a subject reports suicidal ideation or intent at any time, they 
will immediately be referred to a psychiatrist or psychiatric emergency department. 
• 
Schedule study visits for participants who are eligible and available for the duration of the study. 

7.2.2 Enrollment/Baseline 
Visit 2: Baseline Visit – Beginning of Week 1 (Phone Visit) 
• 
Review of current medications. 
• 
Administer THI and VAS questionnaires. 
• 
Issue daily Tinnitus Severity Log/Visual Analog Scale (VAS) log by email. 
7.2.3 Intermediate Visits 
7.2.3.1 Visit 3: End of Week 1 (Office Visit)  
• 
Record adverse events as reported by participant or observed by investigator. 
• 
Record vital signs and auscultate lungs. 
• 
Review current medications and results of VAS log. 
• 
Perform urine pregnancy test, if applicable. 
• 
Administer THI questionnaire.  
• 
Provide the study medication to the participant to use four times daily for the next 2 weeks. 
 
7.2.3.2 Visit 4: Week 2 (Phone Visit) 
• 
Review current medications.  
• 
Assess and record adverse events including dyspnea as reported by participant or observed by 
investigator. 
• 
Record participant’s adherence to treatment program. 
• 
Administer phone Tinnitus Functional Index (TFI) questionnaire. 
7.2.3.3 Visit 5: Week 3 (Office Visit)  
• 
Record vital signs and auscultate lungs. 
• 
Review current medications and results of VAS log. 
• 
Collect urine for electrolyte levels and urine osmolality. Perform urine pregnancy test, if 
applicable. 
• 
Administer THI and Clinical Global Impression – Improvement (CGI-I) questionnaires. 
• 
Record adverse events as reported by participant or observed by investigator. 
• 
Study drug reconciliation and record of participant’s adherence to treatment program. 
• 
Provide the study medication to the participant to use four times daily for the next 2 weeks. 
7.2.3.4 Visit 6: Week 4 (Phone Visit) 
• 
Review current medications.  
• 
Assess and record adverse events including dyspnea as reported by participant or observed by 
investigator. 
• 
Record participant’s adherence to treatment program. 
• 
Administer phone Tinnitus Functional Index (TFI) questionnaire. 
7.2.3.5 Visit 7: Week 5 (Office Visit)  
• 
Record vital signs and auscultate lungs. 
• 
Review current medications and results of VAS log. 
• 
Collect urine for electrolyte levels and urine osmolality. Perform urine pregnancy test, if 
applicable. 
• 
Administer THI and Clinical Global Impression – Improvement (CGI-I) questionnaires. 
• 
Record adverse events as reported by participant or observed by investigator. 
• 
Study drug reconciliation and record of participant’s adherence to treatment program. 
• 
Provide the study medication to the participant to use four times daily for the next 2 weeks. 
7.2.3.6 Visit 8: Week 6 (Phone Visit) 
• 
Review current medications.  

• 
Assess and record adverse events including dyspnea as reported by participant or observed by 
investigator. 
• 
Record participant’s adherence to treatment program. 
• 
Administer phone Tinnitus Functional Index (TFI) questionnaire. 
7.2.3.7 Visit 9: Week 7 (Office Visit)  
• 
Record vital signs and auscultate lungs. 
• 
Review current medications and results of VAS log. 
• 
Collect urine for electrolyte levels and urine osmolality. Perform urine pregnancy test, if 
applicable. 
• 
Administer THI and Clinical Global Impression – Improvement (CGI-I) questionnaires. 
• 
Record adverse events as reported by participant or observed by investigator. 
• 
Study drug reconciliation and record of participant’s adherence to treatment program. 
• 
Provide the study medication to the participant to use four times daily for the next 2 weeks. 
7.2.3.8 Visit 10: Week 8 (Phone Visit) 
• 
Review current medications.  
• 
Assess and record adverse events including dyspnea as reported by participant or observed by 
investigator. 
• 
Record participant’s adherence to treatment program. 
• 
Administer phone Tinnitus Functional Index (TFI) questionnaire. 
7.2.3.9 Visit 11: Week 9 (Office Visit)  
• 
Record vital signs and auscultate lungs. 
• 
Review current medications and results of VAS log. 
• 
Collect urine for electrolyte levels and urine osmolality. Perform urine pregnancy test, if 
applicable. 
• 
Administer THI and CGI-I questionnaires. 
• 
Record adverse events as reported by participant or observed by investigator. 
• 
Study drug reconciliation and record of participant’s adherence to treatment program. 
• 
Randomize and dispense new study drug (active drug or placebo nasal spray) to use for the next 
2 weeks. 
7.2.3.10 Visit 12: Week 10 (Phone Visit) 
• 
Review current medications.  
• 
Assess and record adverse events including dyspnea as reported by participant or observed by 
investigator. 
• 
Record participant’s adherence to treatment program. 
• 
Administer phone Tinnitus Functional Index (TFI) questionnaire. 
7.2.3.11 Visit 13: Week 11 (Office Visit)  
• 
Record vital signs and auscultate lungs. 
• 
Review current medications and results of VAS log. 
• 
Collect urine for electrolyte levels and urine osmolality. Perform urine pregnancy test, if 
applicable. 
• 
Administer THI and CGI-I questionnaires. 
• 
Record adverse events as reported by participant or observed by investigator. 
• 
Record participant’s adherence to treatment program. 
• 
Provide the study medication to the participant to use four times daily for the next 2 weeks. 
7.2.3.12 Visit 14: Week 12 (Phone Visit) 
• 
Review current medications.  

• 
Assess and record adverse events including dyspnea as reported by participant or observed by 
investigator. 
• 
Record participant’s adherence to treatment program. 
• 
Administer phone Tinnitus Functional Index (TFI) questionnaire. 
7.2.3.13 Visit 15: Week 13 (Office Visit)  
• 
Record vital signs and auscultate lungs. 
• 
Review current medications and results of VAS log. 
• 
Collect urine for electrolyte levels and urine osmolality. Perform urine pregnancy test, if 
applicable. 
• 
Administer THI and CGI-I questionnaires. 
• 
Record adverse events as reported by participant or observed by investigator. 
• 
Record participant’s adherence to treatment program. 
• 
Provide the study medication to the participant to use four times daily for the next 2 weeks. 
7.2.3.14 Visit 16: Week 14 (Phone Visit) 
• 
Review current medications.  
• 
Assess and record adverse events including dyspnea as reported by participant or observed by 
investigator. 
• 
Record participant’s adherence to treatment program. 
• 
Administer phone Tinnitus Functional Index (TFI) questionnaire. 
7.2.4 Final Study Visit 
Visit 17: Week 15 (Office Visit)  
• 
Record vital signs and auscultate lungs. 
• 
Review current medications and results of VAS log. 
• 
Draw blood for CMP to be able to compare to baseline levels. 
• 
Perform urine pregnancy test, if applicable. 
• 
Administer THI and CGI-I questionnaires. 
• 
Record adverse events as reported by participant or observed by investigator. 
• 
Study drug reconciliation and record of participant’s adherence to treatment program. 
7.2.5 Withdrawal/Early Termination Visit 
If the participant agrees, any participant who withdraws from the study or is terminated early, will be asked 
to come in for a final visit in which we will record vital signs, obtain blood for CMP, record adverse events, 
and review results of VAS, THI and CGI.   
7.2.6 Unscheduled Visit 
In the event of an unscheduled patient visit, the subject will undergo safety screening – a focused physical 
exam, and blood pressure, temperature, and heart rate documentation.  Depending on the reason for the 
visit, the subject may be referred to the appropriate service for possible adverse event follow up.  All adverse 
events reported by the subject or observed by the investigator will be documented and reported. Aside from 
adverse events, information gathered at these unscheduled visits will not be included in the statistical 
analysis. 
7.3 Concomitant Medications, Treatments, and Procedures 
All concomitant prescription medications taken during study participation will be recorded on the case 
report forms (CRFs). For this protocol, a prescription medication is defined as a medication that can be 
prescribed only by a properly authorized/licensed clinician. Medications to be reported in the CRF are 
concomitant prescription medications, over-the-counter medications and non-prescription medications. 
Review of concomitant medications will occur at every phone and office visit.  

7.4 Prohibited Medications, Treatments, and Procedures 
Current medications are reviewed at each visit. If at any point during the study, a participant begins taking 
dinoprostone or ephedrine, they must stop taking the prohibited medication in order to continue 
participating in the study. 
7.5 Participant Access to Study Agent at Study Closure 
At study end, participants will not be provided additional samples of study medication. 
8 Assessment of Safety 
8.1 Specification of Safety Parameters  
8.1.1 Definition of Adverse Events (AE) 
An adverse event (AE) is any symptom, sign, illness or experience that develops or worsens in severity 
during the course of the study.  Intercurrent illnesses or injuries should be regarded as adverse events.  
Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality: 
• results in study withdrawal 
• is associated with a serious adverse event 
• is associated with clinical signs or symptoms 
• leads to additional treatment or to further diagnostic tests 
• is considered by the investigator to be of clinical significance 
8.1.2 Definition of Serious Adverse Events (SAE) 
Serious Adverse Event 
Adverse events are classified as serious or non-serious.  A serious adverse event is any AE that is:  
• fatal 
• life-threatening 
• requires or prolongs hospital stay 
• results in persistent or significant disability or incapacity 
• a congenital anomaly or birth defect 
• an important medical event 
 
Important medical events are those that may not be immediately life threatening, but are clearly of major 
clinical significance. They may jeopardize the subject, and may require intervention to prevent one of the 
other serious outcomes noted above. For example, drug overdose or abuse, a seizure that did not result 
in in-patient hospitalization, or intensive treatment of bronchospasm in an emergency department would 
typically be considered serious.  
 
All adverse events that do not meet any of the criteria for serious should be regarded as non-serious 
adverse events.  
8.1.3 Definition of Unanticipated Problems (UP) 
Unanticipated Problems Involving Risk to Subjects or Others 
Any incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in nature, severity, or frequency (i.e. not described in study-related documents such 
as the IRB-approved protocol or consent form, the investigators brochure, etc.) 
• Related or possibly related to participation in the research (i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by the 
procedures involved in the research) 
• Suggests that the research places subjects or others at greater risk of harm (including physical, 
psychological, economic, or social harm). 

8.2 Classification of an Adverse Event 
8.2.1 Severity of Event 
For AEs not included in the protocol defined grading system, the following guidelines will be used to 
describe severity. 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities. 
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning. 
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life-threatening or incapacitating. 
8.2.2 Relationship to Study Agent 
The clinician’s assessment of an AE's relationship to study agent (drug, biologic, device) is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the study. If there 
is any doubt as to whether a clinical observation is an AE, the event should be reported. All AEs must 
have their relationship to study agent assessed. In a clinical trial, the study product must always be 
suspect. To help assess, the following guidelines are used. 
• Related – The AE is known to occur with the study agent, there is a reasonable possibility that the 
study agent caused the AE, or there is a temporal relationship between the study agent and event. 
Reasonable possibility means that there is evidence to suggest a causal relationship between the 
study agent and the AE. 
• Not Related – There is not a reasonable possibility that the administration of the study agent 
caused the event, there is no temporal relationship between the study agent and event onset, or 
an alternate etiology has been established. 
8.2.3 Expectedness 
The PI will be responsible for determining whether an AE is expected or unexpected. An AE will be 
considered unexpected if the nature, severity, or frequency of the event is not consistent with the risk 
information previously described for the study agent. 
8.3 Time Period and Frequency for Event Assessment and Follow-Up 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, or upon review by a study monitor. All AEs 
including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate RF. Information to be collected includes event description, time of onset, clinician’s 
assessment of severity, relationship to study product (assessed only by those with the training and 
authority to make a diagnosis), and time of resolution/stabilization of the event. All AEs occurring while on 
study must be documented appropriately regardless of relationship. All AEs will be followed to adequate 
resolution. 
 
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time 
during the study, it will be recorded as an AE. UPs will be recorded in the data collection system 
throughout the study. 
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed. AEs characterized as intermittent require documentation of 
onset and duration of each episode. 
 
The PI will record all reportable events with start dates occurring any time after informed consent is 
obtained until 7 (for non-serious AEs) or 30 days (for SAEs) after the last day of study participation. At 

each study visit, the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events 
will be followed for outcome information until resolution or stabilization.  
 
All unresolved adverse events should be followed by the investigator until the events are resolved, the 
subject is lost to follow-up, or the adverse event is otherwise explained.  At the last scheduled visit, the 
investigator should instruct each subject to report any subsequent event(s) that the subject, or the 
subject’s personal physician, believes might reasonably be related to participation in this study.  The 
investigator should notify the study sponsor of any death or adverse event occurring at any time after a 
subject has discontinued or terminated study participation that may reasonably be related to this study.  
The sponsor should also be notified if the investigator should become aware of the development of 
cancer or of a congenital anomaly in a subsequently conceived offspring of a subject that has participated 
in this study.  
8.4 Reporting Procedures – Notifying the IRB  
8.4.1 Adverse Event Reporting 
Unexpected, related, and harmful adverse events will be reported to the IRB within 10 working days of 
discovery. Subjects will be followed until the resolution of the adverse event. 
8.4.2 Serious Adverse Event Reporting 
In addition to determining the appropriate intervention and ensuring the subject is medically treated, all 
serious adverse events will be reported to the IRB within 24 hours of discovery. 
8.4.3 Unanticipated Problem Reporting 
Incidents or events that meet the OHRP criteria for UPs require the creation and completion of an UP 
report form. It is the principal investigator’s responsibility to report UPs to the IRB. The UP report will 
include the following information: 
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number; 
• A detailed description of the event, incident, experience, or outcome; 
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP; 
• A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP. 
 
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline: 
 
• UPs that are SAEs will be reported to the IRB within 24 hours of the investigator becoming aware 
of the event. 
• Any other UP will be reported to the IRB within 10 working days of the investigator becoming 
aware of the problem. 
• All UPs should be reported to appropriate institutional officials (as required by an institution’s 
written reporting procedures), the supporting agency head (or designee), and OHRP promptly, 
within 2 weeks of the IR’s receipt of the report of the problem from the investigator. 
8.5 Study Halting Rules 
Administration of the study agent will be halted when three grade 3 AEs determined to be “probably 
related” are reported to the PI. The PI will notify the IRB immediately when the third grade 3 event is 
reported and enrollment screens will stop accepting new study participants and the active participants will 
be contacted via phone and if necessary certified mail, to immediately discontinue the spray.  

8.6 Safety Oversight 
It is the responsibility of the Principal Investigator to oversee the safety of the study at his/her site.  This 
safety monitoring will include careful assessment and appropriate reporting of adverse events as noted 
above, as well as the construction and implementation of a site data and safety-monitoring plan. Medical 
monitoring will include a regular assessment of the number and type of serious adverse events.  
 
An independent licensed physician who is a specialist in neurology or otolaryngology will be appointed to 
monitor subject safety. Scott Grossman, MD of the Department of Neurology will perform this role; Dr. 
Grossman is a disinterested third party and is well acquainted with good research practices. In addition to 
individual subject monitoring at each visit, the PI will systematically review accumulated data, adverse 
events, and other relevant events in the study: (1) assess the timeliness, completeness, and quality of the 
data collected, (2) assess the adherence to protocol requirements, especially measures taken to protect 
participant safety, and (3) assess the benefit/risk ratio of study procedures monthly.  
 
A summary of AEs and outcomes of these monthly reviews will be submitted to the IRB every 6 months. 
The PI and Dr. Grossman will meet and review data after every 15 subjects have been enrolled, and will 
be provided with the following data prior to this meeting: (1) all adverse events reported, and (2) subject 
recruitment, enrollment, and dropout numbers. During the meeting, they will review these data and have 
30 days to generate a report, which reflects their opinion of whether the study should be permitted to 
continue and whether any changes need to be made. This report will then be submitted to the IRB. If any 
serious adverse events occur during the study, Drs. Newman and Grossman will be apprised of them 
within 24 hours of the event and will be provided unblinded information with regard to the participants’ 
treatment assignment and corresponding study visit. They will then provide suggestions for the progress 
of the study, as well as determine whether modifications to the protocol are needed. Any additional 
events of pulmonary edema will be reported to the IRB as Reportable New Information, as per NYU SOM 
IRB policy. 
 
Patients will be screened for depression and suicidality at the screening visit and during the weekly 
follow-up visits via direct questioning and in the THI (questions 5 and 21).  Any patient with worsening 
depression or suicidal ideation will be immediately referred to their psychologist/psychiatrist or the 
psychiatric emergency department.  The PI will personally call the appropriate person (clinician, ED, or 
emergency services) as deemed appropriate for the individual subject.  Although there have been reports 
in the literature linking low plasma and CSF oxytocin levels with suicide, oxytocin nasal spray has been 
demonstrated to have antidepressant and anxiolytic effects, and as such, we do not expect treatment to 
worsen depression, but rather improve mood. 
9 Statistical Considerations 
9.1 Plans (SAP) 
The primary analysis is to provide an estimate of the partial eta squared effect size difference between 
placebo and treatment during the blinded phase of the study as well as to provide initial safety and 
tolerability estimates during the initial open label study phase. The effect size will be calculated and 
interpreted using η2=0.2 as a small effect, η2=0.5 as a medium effect, and η2=0.8 as a large effect (20).   
9.2 Statistical Hypotheses 
We hypothesize that treatment with high dose oxytocin nasal spray will result in a large effect size as 
measured by partial eta squared for the difference in mean area under the curve in baseline adjusted VAS 
when compared to placebo during the blinded study phase. 
 
The primary outcome measurement will be the collective area under the VAS curve above the week 3 
baseline as assessed from week 3 to week 6 of the blinded study phase.  The area under the curve will be 
determined using the linear trapezoidal method for each participant after subtracting the baseline (week 3) 
VAS value from each subsequent measure to determine the collective improvement/decline of the VAS 
measurement during the blinded study phase.  The mean and standard deviation of the total area will be 

calculated for each study arm (active drug and placebo) and partial eta squared effect size for the difference 
determined.  This effect size estimate can then be used to power future comparative studies.   
 
The same area under the curve above the baseline VAS metric will be determined separately for the non-
blinded/open label study phase. The inherent bias of non-blinding may influence this metric although the 
relatively larger sample size (n=30) could also improve precision.  Therefore, the area will be presented as 
a descriptive summary using the mean and standard deviation with an effect size estimate.      
 
Secondary endpoints will consist of safety and tolerability metrics including adverse event incidence and 
severity, regimen adherence and voluntary study drop-out rates reported during the non-blinded and 
blinded study phases.  The frequency and percentage of each secondary measure will be determined for 
the non-blinded study phase and by study arm for blinded study phase.  Additionally, any changes in THI 
greater than 1 grade will be determined from week 3 to week 6 of the blinded study phase.  The frequency 
and percentage of these changes will be summarized by study arm.    
9.3 Analysis Datasets 
Efficacy data will be analyzed for all subjects who received at least one dose of study-drug and provided at 
least one endpoint measurement during the non-blinded study phase.  For the blinded study phase efficacy 
data will similarly be analyzed for all randomized patients providing at least one endpoint measurement.  A 
separate per protocol patient population defined as patients providing complete efficacy data will also be 
defined for each study phase.    
 
Safety and tolerability data will be analyzed for all enrolled patients receiving at least one dose of study-
drug during the non-blinded study phase and then for all randomized participants during the blinded study 
phase. 
9.4 Description of Statistical Methods 
Data from this pilot study will be summarized separately for the non-blinded study phase and by study arm 
for the blinded study phases.  The area under the VAS curve after subtracting baseline value will be 
determined using the linear trapezoidal method.  These areas will be determined for the efficacy population 
using the last observation carried forward (LOCF).The mean and standard deviation for the non-blinded 
phase will be determined and the effect size for the mean area from zero calculated.  For the blinded phase 
week 3 (after a 2 week “washout”) will serve as the baseline and the area under the VAS curve from baseline 
will be calculated using LOCF imputation for missing post baseline data.  To avoid potential cross-over 
effects from the 9 week non-blinded phase when all subjects receive active drug, after randomization, 
subjects will receive either active drug or placebo. The first 2 weeks of this 6 week period will be a washout 
period from statistical analysis. While subjects will still receive study drug, data collection for that phase will 
not begin until week 3 of that 6 week period. The mean and standard deviation in area under the VAS curve 
from baseline for each study arm will be determined and the partial eta effect size for the mean difference 
between study arms calculated.  This summary will be performed for the per protocol study population as 
well to investigate the relative influence of missing data on the effect size determination.         
 
Frequencies and percentages for the secondary safety and tolerability endpoints will be determined using 
the ITT patient population for the non-blinded study phase and all randomized participants during the non-
blinded study phase.  The other secondary endpoint, incidence of the change in THI of 1 point or greater, 
will be summarized by study arm for those participants providing at least 1 post-week 3 baseline THI 
measurement.    
 
The analyses will be refined and adjusted in anticipation of study termination and data lock.  
9.4.1 General Approach 
The study design is a pilot, proof of concept, two-phase study. The first non-blinded study phase is to 
provide tolerability, regimen adherence, and initial safety data for the active treatment.  The second phase 
after 2 week washout allows for efficacy comparison of the mean VAS difference from baseline between 

active drug and placebo and incidence of THI changes greater than 1 point.  Please see Schematic of 
Study Design.  
9.4.2 Analysis of the Primary Efficacy Endpoint(s) 
The primary efficacy endpoint is the area under the VAS curve from baseline for all randomized 
participants during the blinded study phase.  The week 3 data after two week washout will serve as the 
baseline and the interval/ratio scaled area determined using the linear trapezoidal method.  The 
expectation is that placebo participants’ post-baseline VAS data will remain relatively consistent with 
baseline values while active treatment will trend post-baseline.  Using an LOCF imputation strategy is 
therefore a conservative strategy for handling missing data by understating trending in the active 
treatment group without introducing trending in the placebo group.  The mean and standard deviation by 
study arm in the area under the VAS curve from baseline will be presented along with the partial eta 
squared effect size estimate for the mean difference between study arms.  The availability of data will be 
determined by study arm at each post-baseline study time point during the blinded study phase to 
investigate the potential influence of missing data.  A per-protocol analysis will also be presented to 
further investigate the influence of missing data on the primary efficacy endpoint.     
 
The area under the VAS curve from baseline will similarly be determined and analyzed separately for the 
open label/non-blinded study phase.  Since this measure is biased by participant knowledge of treatment 
the effect size of the mean VAS area from baseline will be determined and cautiously interpreted.  
 
As included in Section 9.1, the effect size will be calculated and interpreted using η2=0.2 as a small effect, 
η2=0.5 as a medium effect, and η2=0.8 as a large effect (20). These cut-offs will be used to judge the 
strength of the treatment relative to placebo control with medium (η2 ≥ 0.5) considered a treatment 
“success.” 
9.4.3 Analysis of the Secondary Endpoint(s) 
Frequencies and percentages for the secondary safety and tolerability endpoints will be determined using 
the ITT patient population for the non-blinded study phase and all randomized participants during the non-
blinded study phase. Patients withdrawing prematurely from the study will be summarized by study 
timepoint and phase (blinded/non-blinded) and study arm (if applicable) and reason if available.  The total 
number of adverse events (AE) will be summarized by severity, drug-relatedness, and whether it is an SAE 
and then also the total number of participants experiencing an AE will be summarized by study phase and/or 
study arm.  Adherence to treatment regimen will be determined by the percentage of treatment ingested 
per the prescribed treatment amount at each evaluable study time point.  Mean adherence will be 
determined at each study time point during the non-blinded study phase and by study arm during the blinded 
phase.  The other secondary endpoint, incidence of the change in THI of 1 point or greater, will be 
summarized by study arm for those participants providing at least 1 post-week 3 baseline THI 
measurement.    
9.4.4 Safety Analyses 
The total number of adverse events (AE) will be summarized by severity, drug-relatedness, and whether it 
is an SAE and then also the total number of participants experiencing an AE will be summarized by study 
phase and/or study arm.   
9.4.5 Adherence and Retention Analyses 
Adherence to treatment regimen will be determined by the percentage of treatment insufflated per the 
prescribed treatment amount at each evaluable study time point.  Mean adherence will be determined at 
each study time point during the non-blinded study phase and by study arm during the blinded phase. 
Each subject’s medication use and study diary will be reviewed at every visit to measure adherence  
Patients withdrawing prematurely from the study will be summarized by study timepoint and phase 
(blinded/non-blinded) and study arm (if applicable) and reason if available.   

9.4.6 Baseline Descriptive Statistics 
Descriptive summaries will be performed separately for the non-blinded study phase and by study arm for 
the blinded study phase using means, standard deviations, and frequencies and percentages.  There will 
be no inferential statistics used as randomization should eliminate the potential for bias.  
9.4.7 Planned Interim Analysis 
Not applicable 
9.4.7.1 Safety Review 
Administration of the study agent will be halted when three grade 3 AEs determined to be “probably 
related” are reported to the PI. The PI will notify the IRB immediately when the third grade 3 event is 
reported and enrollment screens will stop accepting new study participants and the active participants will 
be contacted via phone and if necessary certified mail, to immediately discontinue the spray.  
9.4.7.2 Efficacy Review 
Not applicable 
9.4.7.3 Additional Sub-Group Analyses 
Not applicable 
9.4.7.4 Multiple Comparison/Multiplicity 
Not applicable 
9.4.7.5 Tabulation of Individual Response Data 
Not applicable 
9.4.7.6 Exploratory Analyses 
Changes in CGI and TFI from baseline (week 3) to week 6 during the blinded study phases will be 
determined and summarized using means and standard deviations for each study arm. A descriptive 
summary using means and standard deviations stratified by dosage group for the treatment subgroup 
during the blinded study phase will be performed. The partial eta squared effect size difference will be 
estimated.   
9.5 Sample Size 
This is a pilot, proof of concept study with the main goal of providing an estimate of the effect size difference 
between treatment and placebo control.  As such the sample size of n=30 will provide sufficient estimates 
of the effect sizes necessary to power a future two-armed randomized study 
9.6 Measures to Minimize Bias 
9.6.1.1 Enrollment/Randomization/Masking Procedures 
After receiving intranasal oxytocin for 9 weeks, participants will be randomized to either intranasal oxytocin 
or placebo. The fellow will use a random number generator to assign subjects to 0 (placebo) or 1 (active 
drug) each time a subject enters the randomized phase of the study. He will use block randomization so 
that treatment group assignments are balanced. This information will be created and stored in the 
Randomization Log. This will be kept securely, stored in a separate Randomization binder to ensure the 
non-blinded fellow only accesses the information as needed to randomize the study medication at visit 11. 
9.6.1.2 Evaluation of Success of Blinding 
Not applicable 
 

9.6.1.3 Breaking the Study Blind/Participant Code 
The blind shall not be broken until the final data analysis, however: 
 
All adverse events (AEs) occurring during the course of the clinical drug trial will be brought to the attention 
of the PI. For significant AEs and serious adverse events (SAEs), the PI will decide on an appropriate 
intervention. Most AEs should not normally lead to the breaking of the treatment assignment code. 
However, if the AE is so severe that it significantly compromises the well-being of the subject, the PI may 
decide to break the blindness code and withdraw the subject from the study. 
 
In the case of AEs of intermediate severity, as when a certain laboratory parameter or clinical sign or 
symptom gradually deviates from normality, the PI will treat these deviations using standard and well 
accepted treatment guidelines and continue to follow the patient until said abnormalities resolve. If standard 
treatments fail to resolve the abnormalities, the PI may decide to break the blind. 
10 Source Documents and Access to Source Data/Documents 
Source data is all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluation of the trial.  Source data are contained in 
source documents.  Examples of these original documents, and data records include: hospital records, 
clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, 
pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions 
certified after verification as being accurate and complete, microfiches, photographic negatives, microfilm 
or magnetic media, x-rays, subject files, and records kept at the pharmacy, at the laboratories, and at 
medico-technical departments involved in the clinical trial. It is acceptable to use CRFs as source 
documents. If this is the case, it should be stated in this section what data will be collected on CRFs and 
what data will be collected from other sources. 
 
The study case report form (CRF) is the primary data collection instrument for the study.  All data 
requested on the CRF must be recorded.  All missing data must be explained.  If a space on the CRF is 
left blank because the procedure was not done or the question was not asked, write “N/D”.  If the item is 
not applicable to the individual case, write “N/A”.  All entries should be printed legibly in black ink.  If any 
entry error has been made, to correct such an error, draw a single straight line through the incorrect entry 
and enter the correct data above it.  All such changes must be initialed and dated.  DO NOT ERASE OR 
WHITE OUT ERRORS.  For clarification of illegible or uncertain entries, print the clarification above the 
item, then initial and date it. 
 
Access to study records will be limited to IRB-approved members of the study team. The investigator will 
permit study-related monitoring, audits, and inspections by the IRB/EC, government regulatory bodies, 
and University compliance and quality assurance groups of all study related documents (e.g. source 
documents, regulatory documents, data collection instruments, study data etc.).  The investigator will 
ensure the capability for inspections of applicable study-related facilities (e.g. pharmacy, diagnostic 
laboratory, etc.). 
 
Participation as an investigator in this study implies acceptance of potential inspection by government 
regulatory authorities and applicable University compliance and quality assurance offices. 
11 Quality Assurance and Quality Control 
QC procedures will be implemented beginning with the data entry system and data QC checks that will be 
run on the database will be generated. Any missing data or data anomalies will be communicated to the 
site(s) for clarification/resolution. 
 
The investigational site will provide direct access to all trial related sites, source data/documents, and 
reports for the purpose of auditing, and inspection by local and regulatory authorities. 

12 Ethics/Protection of Human Subjects 
12.1 Ethical Standard 
The investigator will ensure that this study is conducted in full conformity with Regulations for the 
Protection of Human Subjects of Research codified in 45 CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 
and/or the ICH E6. 
12.2 Institutional Review Board 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be 
submitted to the IRB for review and approval. Approval of both the protocol and the consent form must be 
obtained before any participant is enrolled. Any amendment to the protocol will require review and 
approval by the IRB before the changes are implemented to the study. All changes to the consent form 
will be IRB approved; a determination will be made regarding whether previously consented participants 
need to be re-consented. 
12.3 Informed Consent Process 
12.3.1.1 Consent/Assent and Other Informational Documents Provided to Participants 
Consent forms describing in detail the study agent, study procedures, and risks are given to the 
participant and written documentation of informed consent is required prior to starting 
intervention/administering study product. The following consent material is submitted with this protocol: 
Key Information. 
12.3.1.2 Consent Procedures and Documentation 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study 
and continues throughout the individual’s study participation. Extensive discussion of risks and possible 
benefits of participation will be provided to the participants and their families. Consent forms will be IRB-
approved and the participant will be asked to read and review the document. Subjects will be consented by 
the Principal Investigator, in his office, when they come in for their initial appointment before any study 
procedures can be completed. The PI will be able to answer any questions the individual has about 
participation in the study including the potential risks and benefits. The investigator will explain the research 
study to the participant and answer any questions that may arise.  
 
All participants will receive a verbal explanation in terms suited to their comprehension of the purposes, 
procedures, and potential risks of the study and of their rights as research participants. Participants will 
have the opportunity to carefully review the written consent form and ask questions prior to signing. The 
participants should have the opportunity to discuss the study with their surrogates or think about it prior to 
agreeing to participate. The participant will sign the informed consent document prior to any procedures 
being done specifically for the study. The participants may withdraw consent at any time throughout the 
course of the trial. A copy of the signed informed consent document will be given to the participants for their 
records. The rights and welfare of the participants will be protected by emphasizing to them that the quality 
of their medical care will not be adversely affected if they decline to participate in this study. 
 
None of the subjects enrolled in the study will have impaired decision-making capacity. Only patients who 
are able to provide their own informed consent will be able to participate in this study. Subjects will be asked 
to explain their understanding of participation in the study. The PI will encourage questions as well as ask 
open – ended questions about study procedures. The investigator will reaffirm the subject’s willingness to 
participate in the study, making sure it is understood that their participation is voluntary. 
 
The original signed consent form will be stored on file at the Preston Robert Tisch Center for Men’s 
Health with dates documented on the Pre-Screening Log, Study Subject Tracking Log, and Screening 
Visit Log source document. The consent process, including the name of the individual obtaining consent, 
will be thoroughly documented in the subject’s research record. Any alteration to the standard consent 
process (e.g. use of a translator, consent from a legally authorized representative, consent document 
presented orally, etc.) and the justification for such alteration will likewise be documented.  

12.4 Participant and Data Confidentiality 
Information about study subjects will be kept confidential and managed according to the requirements of 
the Health Insurance Portability and Accountability Act of 1996 (HIPAA).  Those regulations require a 
signed subject authorization informing the subject of the following:  
• What protected health information (PHI) will be collected from subjects in this study 
• Who will have access to that information and why 
• Who will use or disclose that information  
• The rights of a research subject to revoke their authorization for use of their PHI.  
 
In the event that a subject revokes authorization to collect or use PHI, the investigator, by regulation, 
retains the ability to use all information collected prior to the revocation of subject authorization.  For 
subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain 
permission to collect at least vital status (i.e. that the subject is alive) at the end of their scheduled study 
period. 
 
Participant confidentiality is strictly held in trust by the participating investigators and their staff. This 
confidentiality is extended to cover testing of biological samples and genetic tests in addition to the 
clinical information relating to participants. Therefore, the study protocol, documentation, data, and all 
other information generated will be held in strict confidence.  
 
Representatives of the IRB may inspect all documents and records required to be maintained by the 
investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy records 
for the participants in this study. The clinical study site will permit access to such records. 
 
The study participant’s contact information will be securely stored at each clinical site for internal use 
during the study. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by local IRB and Institutional regulations. 
 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will 
be transmitted to and stored at NYU Langone Medical Center. This will not include the participant’s 
contact or identifying information. Rather, individual participants and their research data will be identified 
by a unique study identification number. The study data entry and study management systems used by 
clinical sites and by NYU Langone Medical Center research staff will be secured and password protected. 
At the end of the study, all study databases will be de-identified and archived at the NYU Langone 
Medical Center. 
12.4.1.1 Research Use of Stored Human Samples, Specimens, or Data 
The investigators and research coordinator will take necessary steps to maintain confidentiality of data. 
Paper documents with any personal health information will be stored securely in locked file cabinets when 
not in use. These and electronic data will only be handled by trained study team members when actively 
being used for research. Study staff will code data when appropriate and store data on RedCap, in 
compliance with NYU Langone policies.  
13 Data Handling and Record Keeping 
13.1 Data Collection and Management Responsibilities 
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI. 
The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the 
data reported. 
 
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of 
data. Black ink is required to ensure clarity of reproduced copies. When making changes or corrections, 
cross out the original entry with a single line, and initial and date the change. DO NOT ERASE, 
OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL. 

 
Copies of the electronic CRF (eCRF) will be provided for use as source documents and maintained for 
recording data for each participant enrolled in the study. Data reported in the eCRF derived from source 
documents should be consistent with the source documents or the discrepancies should be explained 
and captured in a progress note and maintained in the participant’s official electronic study record. 
 
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data will be entered into RedCap a 21 CFR Part 11-compliant data capture system. The data 
system includes password protection and internal quality checks, such as automatic range checks, to 
identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from 
the source documents. 
13.2 Study Records Retention 
Study documents will be retained for the longer of 3 years after close-out, 5 years after final 
reporting/publication, or 2 years after the last approval of a marketing application is approved for the drug 
for the indication for which it is being investigated or 2 years after the investigation is discontinued and 
FDA is notified if no application is to be filed or if the application has not been approved for such 
indication.  
13.3 Protocol Deviations 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or Manual of Procedures 
(MOP) requirements. The noncompliance may be either on the part of the participant, the investigator, or 
the study site staff. As a result of deviations, corrective actions are to be developed by the site and 
implemented promptly. 
 
These practices are consistent with ICH E6: 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3 
• 5.1 Quality Assurance and Quality Control, section 5.1.1 
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2. 
 
It is the responsibility of the site PI/study staff to use continuous vigilance to identify and report deviations 
within 5 working days of identification of the protocol deviation, or within 5 working days of the scheduled 
protocol-required activity. 
 
All protocol deviations must be addressed in study source documents. Protocol deviations must be 
reported to the local IRB per their guidelines. The site PI/study staff is responsible for knowing and 
adhering to their IRB requirements. Further details about the handling of protocol deviations will be 
included in the MOP. 
13.4 Publication and Data Sharing Policy 
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical 
trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any research 
project that prospectively assigns human subjects to intervention or concurrent comparison or control 
groups to study the cause-and-effect relationship between a medical intervention and a health outcome. 
Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process-of-care 
changes, and the like. Health outcomes include any biomedical or health-related measures obtained in 
patients or participants, including pharmacokinetic measures and adverse events. The ICMJE policy, and 
the Section 801 of the Food and Drug Administration Amendments Act of 2007, requires that all clinical 
trials be registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by the National 
Library of Medicine. Other biomedical journals are considering adopting similar policies. For interventional 
clinical trials performed under NIH IC grants and cooperative agreements, it is the grantee’s responsibility 
to register the trial in an acceptable registry, so the research results may be considered for publication in 
ICMJE member journals. The ICMJE does not review specific studies to determine whether registration is 
necessary; instead, the committee recommends that researchers who have questions about the need to 

register err on the side of registration or consult the editorial office of the journal in which they wish to 
publish. 
 
FDAAA mandates that a "responsible party" (i.e., the sponsor or designated principal investigator) register 
and report results of certain "applicable clinical trials": 
• Trials of Drugs and Biologics: Controlled, clinical investigations, other than Phase I investigations 
of a product subject to FDA regulation; 
• Trials of Devices: Controlled trials with health outcomes of a product subject to FDA regulation 
(other than small feasibility studies) and pediatric postmarket surveillance studies. 
• NIH grantees must take specific steps to ensure compliance with NIH implementation of FDAAA. 
14 Study Finances 
14.1 Costs to the Participant 
No costs to the participant. 
15 Study Administration 
15.1 Study Leadership 
The Study Team will govern the conduct of the study. The Study Team will be composed of the PI, 
Medical Fellow, and Research Coordinator. 
16 Conflict of Interest Policy 
The independence of this study from any actual or perceived influence, such as by the pharmaceutical 
industry, is critical. Therefore any actual conflict of interest of persons who have a role in the design, 
conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, 
persons who have a perceived conflict of interest will be required to have such conflicts managed in a 
way that is appropriate to their participation in the trial. The study has established policies and procedures 
for all study group members to disclose all conflicts of interest and will establish a mechanism for the 
management of all reported dualities of interest.  
 
Any investigator who has a conflict of interest with this study (patent ownership, royalties, or financial gain 
greater than the minimum allowable by their institution, etc.) must have the conflict reviewed by the NYU 
Langone Conflict of Interest Management Unit (CIMU) with a Committee-sanctioned conflict management 
plan that has been reviewed and approved by the study sponsor prior to participation in this study. All 
NYULMC investigators will follow the applicable conflict of interest policies. 
 
17 References 
1. Bhatt SM Bhatt JM, Lin HW, Bhattacharyya N. Prevalence, Severity, Exposures, and Treatment Patterns 
of Tinnitus in the United States. JAMA Otolaryngol Head Neck Surg. 2016 Oct 1;142(10):959-965.  
2. Han BI, Lee HW, Kim TY, Lim JS, Shin KS. Tinnitus: characteristics, causes, mechanisms, and 
treatments. J Clin Neurol. 2009 Mar;5(1):11-9. doi: 10.3988/jcn.2009.5.1.11. Epub 2009 Mar 31. 
PMID: 19513328; PMCID: PMC2686891. 
3. Moller AR. Sensorineural Tinnitus: Its Pathology and Probable Therapies. Int J Otolaryngol. 
2016;2016:2830157. doi: 10.1155/2016/2830157. Epub 2016 Feb 8. Review. PubMed PMID: 
26977153; PubMed Central PMCID: PMC4761664. 
4. Bhatt JM, Bhattacharyya N, Lin HW. Relationships between tinnitus and the prevalence of anxiety and 
depression. Laryngoscope. 2017 Feb. 127 (2):466-9. 
5. Azevedo AA, Figueiredo RR, Elgoyhen AB, Langguth B, Penido NO, Schlee W. Tinnitus Treatment with 
Oxytocin: A Pilot Study. Front Neurol. 2017 Sep 21;8:494. doi: 10.3389/fneur.2017.00494. 
eCollection 2017.  

6. Guzmán YF, Tronson NC, Jovasevic V, Sato K, Guedea AL, Mizukami H, Nishimori K, Radulovic J 
(September 2013). "Fear-enhancing effects of septal oxytocin receptors". Nature Neuroscience. 16 
(9): 1185–7. doi:10.1038/nn.3465. PMC 3758455. PMID 23872596. 
7: Smith JG, Merrill DC.  Oxytocin for induction of labor. Clin Obstet Gynecol 2006;49: 594-608. 
8. Heytens L, Camu F. Pulmonary edema during cesarean section related to the use of oxytocic drugs. 
Acta Anethesiol Belg 1984;35:155-164 
9. Shimoda Y et al. Two cases of pulmonary edema during and after cesarean section. [Japanese] Masui 
1991;40: 1411-1416. 
10. Ghai B et al. Acute pulmonary oedema following oxytocin administration: a life threatening complication. 
J Indian Med Assoc 2006;104: 261-262. 
11. Milewski M, Goodey A, Lee D, Rimmer E, Saklatvala R, Koyama S, Iwashima M, Haruta . Rapid 
Absorption of Dry-Powder Intranasal Oxytocin. Pharm Res. 2016 Aug;33(8):1936-44. doi: 
10.1007/s11095-016-1929-x. Epub 2016 May 18. PubMed PMID: 27194003. 
12. Quintana DS, Smerud KT, Andreassen OA, Djupesland PG. Evidence for intranasal oxytocin delivery 
to the brain: recent advances and future perspectives. Ther Deliv. 2018 Jul;9(7):515-525. doi: 
10.4155/tde-2018-0002. PubMed PMID: 29943688. 
13. Dal Monte O, Noble PL, Turchi J, Cummins A, Averbeck BB. CSF and blood oxytocin concentration 
changes following intranasal delivery in macaque. PLoS One. 2014 Aug 18;9(8):e103677. doi: 
10.1371/journal.pone.0103677. eCollection 2014. PubMed PMID: 25133536; PubMed Central 
PMCID: PMC4136720. 
14. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-
Lindenberg A (December 2005). "Oxytocin modulates neural circuitry for social cognition and fear 
in humans". The Journal of Neuroscience. 25 (49): 11489–93. doi:10.1523/JNEUROSCI.3984-
05.2005. PMID 16339042..  
15. Marlin BJ, Mitre M, D'amour JA, Chao MV, Froemke RC. Oxytocin enables maternal behaviour by 
balancing cortical inhibition. Nature. 2015 Apr 23;520(7548):499-504. doi: 10.1038/nature14402. 
Epub 2015 Apr 15. PubMed PMID:25874674; PubMed Central PMCID: PMC4409554. 
16. Forsling ML, Chard T, Boyd NHR.  The dissociation of the immunological and biological activity of 
oxytocin: in vivo studies.  In Ed KE,Hunter WM, eds. Radioimmunoassay Methods (European 
Workshop)> New York: Churchill Livingstone, 1971: 549-558. 
17. MacDonald E, Dadds MR, Brennab JL, et al.  A review of safety, side-effects and subjective reactions 
to intranasal oxytocin in human research. Psychoneuroendocrinology 2011;36: 1114-1126. 
18. Ohlsson B, Truedsson M, Bengtsson M, et al.  Effects of long-term treatment with oxytocin in chronic 
constipation; a double-blind, placebo-controlled pilot trial. Neurogastroenterol Motil 2005;17: 698-
704. 
19. Cochran DM, Fallon D, Hill M, Frazier JA. The role of oxytocin in psychiatric disorders: a review of 
biological and therapeutic research findings. Harv Rev Psychiatry. 2013 Sep-Oct;21(5):219-47. doi: 
10.1097/HRP.0b013e3182a75b7d. Review. PubMed PMID: 24651556; PubMed Central PMCID: 
PMC4120070 
20. Bakermans-Kranenburg MJ, van I Jzendoorn MH. Sniffing around oxytocin: review and meta-analyses 
of trials in healthy and clinical groups with implications for pharmacotherapy. Transl Psychiatry. 
2013 May 21;3(5):e258. doi: 10.1038/tp.2013.34. PMID: 23695233; PMCID: PMC3669921. 
21. Epperson CN, McDougle CJ, Price LH. Intranasal oxytocin in obsessive-compulsive disorder. Biol 
Psychiatry. 1996 Sep 15;40(6):547-9. PubMed PMID: 8879477.  
22. Ansseau JJ, Legrus C, Mormont JL, et al. Intranasal oxytocin in obsessive-compulsive disorder. 
Psychoneuroendocrinology 1987; 12: 231-236. 
23. Seifer DB, Sandberg EC, Ueland K, Sladen RW. Water intoxication and hyponatremic 
encephalopathyfrom the use of an oxytocin nasal spray. A case report. J. Reprod Med. 1985; 30: 
225-228.; Hubner-Mayer B. Pseudotumor cerebri from intranasal oxytocin and excessive fluid 
intake. Lancet 1996; 347: 623. 
24. Epperson CN, McDougle CJ, Pierce LH. Intranasal oxytocin in trichotillomania. Biol Psychiatry 1996; 
40:559. 
25. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ, Hickie IB. Intranasal oxytocin 
improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry. 2010 Apr 
1;67(7):692-4. doi: 10.1016/j.biopsych.2009.09.020. Epub 2009 Nov 7. PubMed PMID: 19897177. 

26. Newman CW, Jacobson GP, Spitzer JB. Development of the Tinnitus Handicap Inventory. Arch 
Otolaryngol Head Neck Surg. 1996 Feb;122(2):143-8.  
27. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. 
Psychiatry (Edgmont). 2007 Jul;4(7):28-37.  
28. Fackrell K, Hoare DE. Questionnaires to Measure Tinnitus Severity. ENT & Audiology News. 
2014;22(6). 
29. Oxytocin Nasal Spray package insert. Costa Mesa, CA: Harbor Compounding Pharmacy; 2017. 
30. Keppel, G., & Wickens, T. D. Design and Analysis: A Researcher’s Handbook (4th ed.) 2004. 
31. Langguth B, Elgoyhen AB, Cederroth CR. Therapeutic Approaches to the Treatment of Tinnitus. Annu 
Rev Pharmacol Toxicol. 2019 Jan 6;59:291-313. doi:10.1146/annurev-pharmtox-010818-021556. 
Epub 2018 Jul 25.  
32. Weisman O, Zagoory-Sharon O, Feldman R.  "Intranasal oxytocin administration is reflected in human 
saliva". Psychoneuroendocrinology.2012 37 (9): 1582–6. 
33. Watts EJ, Fackrell K, Smith S, Sheldrake J, Haider H, Hoare DJ. Why Is Tinnitus a Problem? A 
Qualitative Analysis of Problems Reported by Tinnitus Patients. Trends Hear. 2018 Jan-
Dec;22:2331216518812250. doi:10.1177/2331216518812250.  

18 Schedule of Events 
 
Activity 
Scree-
ning 
Visit  
(Week 
0) 
Base-
line 
Visit 
(Start 
of  
Wk 1) 
Phone 
Visit 
3 
(End 
of 
Wk1) 
Visit 4 
(Wk2) 
Phone 
Visit 
5 
(Wk3) 
Visit 
6 
(Wk4) 
Phone 
Visit 
7 
(Wk5) 
Visit 
8 
(Wk6) 
Phone 
Visit 
9 
(Wk7) 
Visit 
10 
(Wk8) 
Phone 
Visit 
11 
(Wk9) 
Visit 
12 
(Wk 
10) 
Phone 
Visit 
13 
(Wk 
11) 
Visit 
14 
(Wk 
12) 
Phone 
Visit 
15 
(Wk 
13) 
Visit 
16 
(Wk 
14) 
Phone 
Visit 
17 
(Wk 
15) 
 
Study team 
procedures 
  
  
  
  
  
  
 
 
 
 
 
 
 
 
 
 
 
Consent 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Medical History 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Physical Exam 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vital signs 
X 
X 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Lung auscultation 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Medication Review 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Study drug 
dispensation  
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
 
Randomization 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
Participant study 
drug compliance 
check 
 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
Questionnaires 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Cardiology 
assessments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Electrocardiogram 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laboratory 
Assessments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Comprehensive 
Metabolic Panel 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
Urine electrolytes 
X 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
 
Urine osmolality  
X 
 
 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
 
Urine pregnancy 
test 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X 
 
X